[HTML][HTML] Disease severity, fever, age, and sex correlate with SARS-CoV-2 neutralizing antibody responses
S Schlickeiser, T Schwarz, S Steiner, K Wittke… - Frontiers in …, 2021 - frontiersin.org
Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …
Disease severity, fever, age, and sex correlate with SARS-CoV-2 neutralizing antibody responses.
S Schlickeiser, T Schwarz, S Steiner, K Wittke… - 2021 - cabidigitallibrary.org
Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …
Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses
S Schlickeiser, T Schwarz, S Steiner… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …
Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses
S Schlickeiser, T Schwarz, S Steiner… - Frontiers in …, 2021 - refubium.fu-berlin.de
Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …
[PDF][PDF] Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses
S Schlickeiser, T Schwarz, S Steiner… - Front. Immunol. 11 …, 2021 - scienceopen.com
The predictive discrimination for PRNT50≥ 1: 320 was reasonably good with AUC: 0.86
(with 95% CI: 0.79–0.92). Combining clinical and ELISA-based pre-screening, assessment …
(with 95% CI: 0.79–0.92). Combining clinical and ELISA-based pre-screening, assessment …
Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses.
S Schlickeiser, T Schwarz, S Steiner, K Wittke… - Frontiers in …, 2021 - europepmc.org
Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …
[HTML][HTML] Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses
S Schlickeiser, T Schwarz, S Steiner… - Frontiers in …, 2020 - ncbi.nlm.nih.gov
Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …
Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses.
S Schlickeiser, T Schwarz, S Steiner, K Wittke… - Frontiers in …, 2021 - europepmc.org
Clinical trials on the use of COVID-19 convalescent plasma remain inconclusive. While data
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …
on safety is increasingly available, evidence for efficacy is still sparse. Subgroup analyses …